Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Jiangxi Boya Bio-Pharma to Buy Majority Stake in Haikang Biological

publication date: Dec 12, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Jiangxi Boya Bio-Pharmaceutical will pay up to 115.6 million RMB ($18.5 million) to purchase a 68% stake in Zhejiang Haikang Biologicals. Both companies are involved in blood products and plasma collection. The deal was structured to include earn-out provisions over the next three years and will allow Boya to increase its ownership of Haikang if specific conditions are met. Boya bought the 68% stake from a third party. More details....

Stock Symbol: (SHA: 300294)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors